Effects of the Salt-Processing Method on the Pharmacokinetics and Tissue Distribution of Orally Administered Morinda officinalis How. Extract

Table 5

Extraction recoveries in rat plasma and tissues (n = 5).

Matrix	Compounds	Conc. (μg/mL)	Recoveries (%)	RSD (%)
Plasma	Rubiadin	3.6	88.34	7.03
		50.6	95.08	1.89
		712.5	96.39	0.93
	Rubiadin 1-methyl ether	3.9	81.89	3.24
		54.6	93.42	3.13
		765	94.05	1.44
	Monotropein	0.14	95.51	3.66
		2	91.97	3.88
		28.1	97.60	1.10
Small intestine	Rubiadin	0.21	85.24	3.91
		0.98	91.09	4.05
		4.63	96.21	1.15
	Rubiadin 1-methyl ether	0.15	92.44	2.20
		0.72	91.39	8.03
		3.49	86.97	3.60
	Monotropein	1.41	98.27	1.83
		6.2	98.64	1.03
		28.13	92.95	0.02
Liver	Rubiadin	0.21	89.37	2.15
		0.98	88.98	1.13
		4.63	94.16	2.78
	Rubiadin 1-methyl ether	0.15	88.89	7.21
		0.72	85.97	3.28
		3.49	90.84	1.87
	Monotropein	1.41	97.07	3.25
		6.2	97.67	1.61
		28.13	96.41	0.91
Kidney	Rubiadin	0.21	88.73	4.56
		0.98	82.07	8.44
		4.63	93.59	4.07
	Rubiadin 1-methyl ether	0.15	88.89	4.26
		0.72	93.61	6.61
		3.49	89.98	3.55
	Monotropein	1.41	93.95	4.96
		6.2	93.41	4.95
		28.13	94.47	0.87
Lung	Rubiadin	0.21	80.63	2.46
		0.98	80.07	6.59
		4.63	83.97	1.47
	Rubiadin 1-methyl ether	0.15	91.11	3.30
		0.72	86.67	5.77
		3.49	88.96	5.08